The aim of the study is to examine the effects of pharmacological treatment for obesity on BMI trajectories and metabolic markers among patients in routine clinical care. A retrospective observational study. By collecting and analysing real-life data from the first children and adolescents in Sweden who have been offered pharmacological treatment for obesity, the results can contribute to a better understanding of how these treatments function in practice.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change in Body Mass Index Standard Deviation Score (BMI SDS) over time
Timeframe: The primary outcome, change in BMI SDS, will be evaluated at -12 months (pre-baseline), at baseline (0 months), and at +3-6, +12, and +18 months following treatment initiation.